Sermorelin vs. Tesamorelin: How the Two GHRH Analogs Actually Differ

The short answer is that sermorelin and tesamorelin share a mechanism but differ in regulatory status: tesamorelin is an FDA-approved prescription drug for one specific condition, while compounded sermorelin is not FDA-approved and is prescribed more broadly for growth-hormone-axis support.

What sermorelin and tesamorelin have in common is their family: both are GHRH analogs. Rather than giving you synthetic growth hormone, they signal the pituitary gland to release your own GH through the body's existing pathway. A two-page 2006 commentary in Clinical Interventions in Aging argued that this approach is more physiologic than direct HGH because it preserves the body's own feedback regulation (Walker, 2006). That is a mechanistic argument, not trial evidence.

That shared mechanism is why the two get compared so often. The differences are mostly about regulatory status, intended use, and availability — not about being fundamentally different kinds of molecules.

Tesamorelin is a stabilized GHRH analog marketed as Egrifta, and it is FDA-approved — a meaningful distinction. Its approval is narrow and specific: it's indicated for the reduction of excess visceral abdominal fat in patients with HIV-associated lipodystrophy, an indication established through controlled clinical trials (Falutz et al., 2007).

Two implications worth being clear about:

• It's a specialty drug for a diagnosed condition, prescribed and monitored in that context — not a general wellness or optimization product, despite how it's sometimes discussed online.
• Its FDA approval is a genuine advantage on the dimensions approval speaks to: it has been through formal review for that indication, with an established label and safety profile.

Protocol MD does not offer tesamorelin. Its approved use falls outside the scope of what we provide, and we're not in a position to prescribe or dispense it.

Sermorelin is also a GHRH analog, but its regulatory situation is different. It was FDA-approved as Geref for growth hormone deficiency in children and for diagnostic testing; the manufacturer discontinued it in 2008, and no adult indication was ever approved. Compounded sermorelin is not FDA-approved. It's prepared by licensed 503A compounding pharmacies and prescribed by physicians, after evaluation, for growth-hormone-axis support, which is an unapproved use.

Practically, that means sermorelin's use is grounded in clinical practice and physician judgment rather than a specific FDA-approved indication — which is exactly why who prescribes it and where it comes from matters so much. A physician-prescribed, pharmacy-compounded product with a real evaluation behind it is a fundamentally different thing from a "research-only" vial bought online, even when the molecule name matches.

The differences that matter between sermorelin and tesamorelin are regulatory status, intended population, formulation and availability.

• Regulatory status. Tesamorelin is FDA-approved for a defined indication; compounded sermorelin is not FDA-approved, and its adult use is unapproved. This is the single biggest difference.
• Intended population. Tesamorelin is for a diagnosed medical condition. Sermorelin is used more broadly for GH-axis support in appropriate candidates.
• Formulation and duration. Tesamorelin was engineered for greater stability; sermorelin is shorter-acting, which some prescribers view as producing a more pulse-like signal.
• Availability. Tesamorelin is a specialty pharmacy product tied to its indication; sermorelin is more commonly available through compounding pharmacies with a prescription.

Which one is right for you is not a question this article can answer, and be skeptical of any page that claims otherwise.

If you have the specific condition tesamorelin is approved to treat, that's a conversation with the physician managing that condition — and its FDA approval matters. If you're exploring growth-hormone-axis support more generally, sermorelin is the option more commonly used in that context, and it requires a physician evaluation to determine whether it's appropriate for you at all.

What's not a good approach for either: deciding based on a forum thread and sourcing the compound yourself. Both are prescription products, and both have gray-market imitations circulating that carry real risks unrelated to the molecules themselves. The right choice for you comes from a physician evaluation, not from a comparison page.

Protocol MD offers physician-prescribed, 503A-compounded sermorelin and not tesamorelin because growth-hormone-axis support is within the scope of what we do, and because sermorelin fits that use under physician supervision. Tesamorelin's approved indication is a specific HIV-related condition managed in a different clinical context, so we don't offer it.

We'd rather tell you that plainly than pretend the comparison only has one reasonable answer. Our side of it is the Protocol MD Sermorelin assessment: an online intake, a review by a US-licensed physician, and a 503A-compounded prescription only if the physician approves. Here's how Protocol MD's physician-prescribed sermorelin works, and our sermorelin dosage guide covers how a protocol is actually set.

The bottom line is that sermorelin and tesamorelin are close cousins mechanically (both GHRH analogs that work through your own growth-hormone pathway), but they occupy different regulatory and clinical worlds. Tesamorelin is FDA-approved for a specific diagnosed condition and is managed in that context. Sermorelin is compounded and prescribed more broadly for growth-hormone-axis support, which makes the legitimacy of the source and the quality of the physician evaluation the deciding factors. Protocol MD offers sermorelin, not tesamorelin — and either way, this is a decision to make with a licensed physician rather than from a comparison chart.